Literature DB >> 32059634

Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.

Emily K Zern1, Susan Cheng1, Aaron M Wolfson2, Michele A Hamilton1, Michael R Zile3, Scott D Solomon4, Michelle M Kittleson1.   

Abstract

Entities:  

Keywords:  angiotensin; diuresis; ejection fraction; heart failure; hypertension

Mesh：

Substances：

Year:  2020        PMID： 32059634      PMCID： PMC7027923          DOI： 10.1161/CIRCHEARTFAILURE.119.006696

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  6 in total

1.  The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.

Authors:  Mandeep R Mehra; Charles E Canter; Margaret M Hannan; Marc J Semigran; Patricia A Uber; David A Baran; Lara Danziger-Isakov; James K Kirklin; Richard Kirk; Sudhir S Kushwaha; Lars H Lund; Luciano Potena; Heather J Ross; David O Taylor; Erik A M Verschuuren; Andreas Zuckermann
Journal:  J Heart Lung Transplant       Date:  2016-01       Impact factor: 10.247

2.  Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.

Authors:  Richard T Clements; Alexander Vang; Ana Fernandez-Nicolas; Nouaying R Kue; Thomas J Mancini; Alan R Morrison; Krishna Mallem; Danielle J McCullough; Gaurav Choudhary
Journal:  Circ Heart Fail       Date:  2019-11-11       Impact factor: 8.790

3.  Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.

Authors:  Adrian J Hobbs; Amie J Moyes; Reshma S Baliga; Dipa Ghedia; Rachel Ochiel; Yvonne Sylvestre; Caroline J Doré; Kashfia Chowdhury; Kate Maclagan; Harriet L Quartly; Reecha Sofat; Angelique Smit; Benjamin E Schreiber; Gerry J Coghlan; Raymond J MacAllister
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

4.  Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.

Authors:  Nasrien E Ibrahim; Cian P McCarthy; Shreya Shrestha; Hanna K Gaggin; Renata Mukai; Jackie Szymonifka; Fred S Apple; John C Burnett; Seethalakshmi Iyer; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2019-03-26       Impact factor: 24.094

5.  Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.

Authors:  Zen-Kong Dai; Chong-Chao Hsieh; Chee-Yin Chai; Jiunn-Ren Wu; Arco Y Jeng; Shah-Hwa Chou; Bin-Nan Wu; Jwu-Lai Yeh; Ing-Jun Chen; Mian-Shin Tan
Journal:  Pediatr Pulmonol       Date:  2010-11

6.  Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.

Authors:  Reshma S Baliga; Lan Zhao; Melanie Madhani; Belen Lopez-Torondel; Cristina Visintin; David Selwood; Martin R Wilkins; Raymond J MacAllister; Adrian J Hobbs
Journal:  Am J Respir Crit Care Med       Date:  2008-08-08       Impact factor: 21.405
  6 in total
  6 in total

Review 1.  Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors:  Nicholas E King; Evan Brittain
Journal:  Pulm Circ       Date:  2022-01-18       Impact factor: 2.886

Review 2.  Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension.

Authors:  Adrija Hajra; Israel Safiriyu; Prasanth Balasubramanian; Rahul Gupta; Selia Chowdhury; Abhishek J Prasad; Akshay Kumar; Deepak Kumar; Baseer Khan; Roberta S F Bilberry; Ankit Sarkar; Paras Malik; Wilbert S Aronow
Journal:  Curr Probl Cardiol       Date:  2022-04-29       Impact factor: 16.464

3.  Getting the "Right" Perspective on Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Frederik H Verbrugge; Barry A Borlaug
Journal:  J Am Heart Assoc       Date:  2020-06-18       Impact factor: 5.501

4.  Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.

Authors:  Sepideh Taghavi; Maryam Chenaghlou; Marzieh Mirtajaddini; Ahmad Amin; Nasim Naderi
Journal:  J Cardiovasc Thorac Res       Date:  2020-11-28

5.  Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.

Authors:  Jeffrey S Tran; Ofer Havakuk; Jennifer M McLeod; Jennifer Hwang; Hoi Yan Kwong; David Shavelle; Michael R Zile; Uri Elkayam; Michael W Fong; Luanda P Grazette
Journal:  ESC Heart Fail       Date:  2021-01-31

6.  Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.

Authors:  Mohammad Abumayyaleh; Jonathan Demmer; Carina Krack; Christina Pilsinger; Ibrahim El-Battrawy; Michael Behnes; Assem Aweimer; Andreas Mügge; Siegfried Lang; Ibrahim Akin
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-30       Impact factor: 3.283
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.